Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...

Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

In the past month, Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic headwinds. A key catalyst was last week’s announcement ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...